A clue to diagnosing connective tissue disease-associated interstitial lung disease.

Correspondence During the past 3 years, Dr Chapman has received compensa tion for consulting with AstraZeneca, Boehringer-Ingelheim, CSL Behring, GlaxoSmithKline, Merck Frosst, Novartis, Nycomed, Pfi zer, Roche, Schering Plough, and Telacris; has undertaken research funded by AstraZeneca, Boehringer-Ingelheim, CSL Behring, Forest Laboratories, GlaxoSmithKline, Novartis, Parangenix, Roche, and Talecris; and has participated in continu ing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis, Nycomed, Pfi zer, and Talecris. Drs L. G. Fritscher, C. C. Fritscher, and Balter and Ms Bradi have reported that no potential confl icts of interest exist with any companies/organizations whose products or services may be discussed in this article. Correspondence to: Leandro G. Fritscher, MD, Avenida Ipiranga, 6690/501, Porto Alegre, RS, Brazil; e-mail: leandro.fritscher@ pucrs.br © 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( http :// www . chestpubs . org / site / misc / reprints . xhtml ). DOI: 10.1378/chest.10-2483